Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone

• US 20030224051A1
• Filed: 05/28/2003
• Published: 12/04/2003
• Est. Priority Date: 05/31/2002
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Ayer, Atul D., Shivanand, Padmaja, Allphin, Clark P., Fink, Tracy A., Johnson, Deborah J.
• Application Number:
  US10/447,910
• Publication Number:
  US 20030224051A1
• Time in Patent Office: Days
• US Class Current: 424/473
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids

Abstract

Dosage forms, compositions and methods for the controlled release of oxycodone over a prolonged period of time are described. The present invention discloses a novel means for delivering varying doses of oxycodone using a drug composition having only oxycodone, a polymer carrier and varying amounts of salt to provide a particular viscosity of the hydrated drug core for delivery of the drug at the desired release rate. The present invention functions by modulating the viscosity of the hydrated drug layer in operation by the addition or reduction of salts in the drug composition. The system is independent of solubility enhancers or pH modifiers. The sustained release dosage forms provide therapeutically effective average steady-state plasma oxycodone concentrations when administered once per day.

Claims

1. A controlled release oral dosage form for once-a-day administration of oxycodone comprising:

(a) a drug core which comprises;

(i) an osmotic agent; and

(ii) a low dose of oxycodone, or one or more pharmaceutically-acceptable salts thereof;

(b) a semipermeable membrane at least partially surrounding the drug core; and

(c) an exit orifice through the semipermeable membrane which communicates with the drug core so as to allow release of the oxycodone to the environment;

wherein the drug core upon hydration in the environment exhibits a viscosity of about 50 cps to 100 cps.

2. The dosage form of claim 1 wherein the osmotic agent is sodium chloride.

3. The dosage form of claim 1 wherein the osmotic agent is in an amount of 0% to about 25% by weight of the total dosage form.

4. The dosage form of claim 1 wherein the osmotic agent is in an amount of 15% to about 25% by weight of the total dosage form.

5. The dosage form of claim 1 wherein the low dose of oxycodone is about 5% to about 15% by weight of the total dosage form.

6. The dosage form of claim 1 wherein the drug core further comprises a polyalkylene oxide polymer.

7. The dosage form of claim 1 further comprising an expandable layer which does not comprise oxycodone.

8. A method of treating a condition in a subject responsive to the administration of oxycodone comprising orally administering the dosage form of claim 1 to the subject.

9. A controlled release oral dosage form for once-a-day administration of oxycodone comprising:

(a) a drug core which comprises;

(i) a high dose of oxycodone, or one or more pharmaceutically-acceptable salts thereof; and

(ii) does not comprise an osmotic agent;

(b) a semipermeable membrane at least partially surrounding the drug core; and

(c) an exit orifice through the semipermeable membrane which communicates with the drug core so as to allow release of the oxycodone to the environment;

wherein the drug core upon hydration in the environment exhibits a viscosity of about 50 cps to about 100 cps.

10. A method of treating a condition in a subject responsive to the administration of oxycodone comprising orally administering the dosage form of claim 9 to the subject.

11. The dosage form of claim 9, wherein the high dose of oxycodone is about 15% to about 40% by weight of the total dosage form.

12. The dosage form of claim 9, wherein the high dose of oxycodone is about 17.7% to about 36.8% by weight of the total dosage form.

13. The dosage form of claim 9, which further comprises an osmotic agent.

14. A controlled release oral dosage form for once-a-day administration of oxycodone comprising:

(a) a drug core which comprises;

(i) an osmotic agent; and

(ii) a low dose of oxycodone, or one or more pharmaceutically-acceptable salts thereof;

(b) a semipermeable membrane at least partially surrounding the drug core; and

(c) an exit orifice through the semipermeable membrane which communicates with the drug core so as to allow release of the oxycodone to the environment;

wherein the release index is about 20% to 100%.

15. A controlled release oral dosage form for once-a-day administration of oxycodone comprising:

(a) a drug core which comprises;

(i) a high dose of oxycodone, or one or more pharmaceutically-acceptable salts thereof; and

(ii) does not comprise an osmotic agent;

(b) a semipermeable membrane at least partially surrounding the drug core; and

(c) an exit orifice through the semipermeable membrane which communicates with the drug core so as to allow release of the oxycodone to the environment;

wherein the release index is about 20% to 100%.

16. An osmotic drug composition comprising a high dose of oxycodone and a polymer carrier and not comprising an osmotic agent.